Engineered Tau Antibody Binding Affinity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibodies targeting tau have limitations such as low binding affinity, immunogenicity, aggregation issues, and stability problems, which hinder their effectiveness in treating neurodegenerative diseases like Alzheimer's and Progressive Supranuclear Palsy.
Innovation Solution
Development of a monoclonal antibody with specific amino acid modifications in its complementarity determining regions (CDRs) and framework regions, engineered to improve binding affinity, reduce immunogenicity, and enhance chemical and physical stability, specifically designed to target tau aggregates and inhibit their propagation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional tau antibodies are used, then tau aggregation can be targeted, but binding affinity is insufficient and immunogenicity problems arise
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequences in the CDR regions of the antibody to optimize binding affinity to tau aggregates while reducing immunogenicity. Specifically, the CDR1, CDR2, and CDR3 regions were engineered with specific amino acid substitutions to enhance specificity and affinity for pathological tau conformations.
Solution Approach 2:
The patent creates a composite antibody structure by combining humanized framework regions with engineered CDR regions. This composite approach allows the antibody to maintain human compatibility (reducing immunogenicity) while incorporating optimized binding regions for high-affinity tau aggregate recognition.
2Reliability
If tau antibodies are developed for therapeutic use, then disease modification may be achieved, but aggregation and stability problems hinder effectiveness
Solution Approach 1:
The patent optimizes stability parameters by engineering the framework regions and constant domains of the antibody. Specific amino acid modifications were introduced to enhance resistance to aggregation and improve overall structural stability, ensuring the antibody remains effective during storage and administration.
Solution Approach 2:
The patent develops a highly stable antibody formulation that resists aggregation and degradation, effectively creating a long-lasting therapeutic agent that maintains its functional integrity throughout its therapeutic lifecycle.
3Reliability
If monoclonal antibody engineering is performed to improve binding, then affinity increases, but complexity of development increases
Solution Approach 1:
The patent systematically optimized binding affinity by making targeted amino acid substitutions in the CDR regions based on structural analysis of tau aggregates. This rational design approach, rather than random screening, streamlined the development process while achieving high affinity.
Solution Approach 2:
The patent utilized humanized antibody frameworks as templates to reduce immunogenicity while maintaining binding capability. By copying successful structural elements from known stable antibodies and combining them with engineered CDRs, the development complexity was managed more effectively.
Data Source
AI summary
Monoclonal antibodies to human tau aggregate, compositions comprising such tau antibodies, and methods of using such tau antibodies for the treatment of neurodegenerative diseases including Alzheimer's disease, Progressive Supranuclear Palsy and Pick's disease.